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Dedicated to all the rebels out there,
whom refuse the convenient,
until proven true.
We need you now more than ever before
What does not kill me makes me stronger
Friedrich Nietzsche
ABSTRACT
Malignant mesothelioma has a mean overall survival of around 1 year and lung
adenocarcinoma with pleural spread has a mean overall survival of around 5 months. Both
diseases cause fluid accumulation in the pleura, which is drained to alleviate associated
symptoms such as shortness of breath. This fluid oft contains exfoliated tumor cells.
All chemotherapy regiments in use against malignant mesothelioma and lung
adenocarcinoma with pleural spread have an objective response rate of 30-40%, and they all
increase mean overall survival with a mere 3 months. The choice of drug combinations in the
chemotherapy regiments are determined based on the statistically best drug combination.
However, due to tumor heterogeneity, it is unclear whether some patients would respond
better to an alternative treatment rather than the gold standard.
To test this hypothesis, tumor cells were isolated from the effusions and cultured together
with cytostatic drugs. After 48 or 72 h, the toxicity was measured using an automated live /
dead assay, a colorimetric assay or a flow cytometer based assay and compared to an
untreated control. The obtained data was then compared with patient journals, either overall
survival or effect of drug treatment.
Such drug exposure assays have been performed for long, however, no drug exposure assay
have seen clinical use outside of smaller studies. The work described in this thesis attempted
a number of methods of improving these assays, most prominently by attempting to make the
measurements tumor specific, as there is often a substantial admixture of benign
inflammatory cells. Also other refinements were tested, such as increasing the concentrations
of the tested drugs to above what is found in the blood of patients in order to elicit meaningful
response during in vitro short drug exposure times.
The thesis concludes with a promising study, using the flowcytometer to make the readouts
tumor cell specific and to show high variation. Initial data suggests this tumor specific assay
indeed is able to predict patient response to given drugs.
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11 INTRODUCTION
1.1 Malignancies of the serosal cavities
1.1.1 General
A serosal cavity is the space between the visceral- and a parietal mesothelium, lubricated by
an interstitial serosal fluid. There are four serosal cavities: the pleura that lines the lungs,
the pericardium that envelops the heart, the peritoneum that lines the intestines and the
tunica vaginalis, a rest of peritoneum in the testis capsule. The physiologic function of the
serosal cavities is to reduce friction to allow movement between internal organs.
The mesothelium is a membrane consisting of a single layer of mesothelial cells with flat
epithelioid phenotype. These cells rest on a basement membrane, beneath which lies the
mesothelial stroma, a layer of fibroblast-like mesothelial precursor cells [1]. Neither cell
type is terminally differentiated, and they both have the capacity to participate in healing of
mesothelial defects. The serosal cavities have mesodermal origin, and mesothelial cell
express N-CAM as its main adhesion molecule, thus, the mesothelium is mesenchymal by
definition. Due to the dual nature of mesenchymal as well as epithelioid phenotype, these
cells express a mixture of epithelial and mesenchymal markers, indicating an
immunophenotype intermediate to epithelium and mesenchyme.
Like their benign precursors, malignant mesotheliomas (MM) can be either epitheloid or
fibroblast-like, or even a mixture of both types. Thus, MM are subcategorized as epithelioid,
sarcomatoid and biphasic. The basic biology between these growth patterns is still unclear,
and certain cell lines derived from MM can be switched from epithelioid to sarcomatoid
simply by changing the culture medium [2]. It should be noted, however, that it is not
known to which extent this transition from one to the other phenotype is due to the
environmental change causing a phenotype switch, or because the different conditions favor
clonal outgrowth of either phenotype. In general, MM has a poor prognosis with an average
overall survival (OS) of around 1 year. Still, a small proportion of the patients survive for 5
years or more. The sarcomatoid phenotype, however, has a substantially worse prognosis,
with an average OS of 4 months [3].
MM is clearly linked to asbestos exposure [4], and it is generally believed that the
spontaneous cancer rate of MM is very low. Asbestos have been forbidden in Sweden since
1982, with a first step taken in 1972, banning crocidolite, the most carcinogenic form of
asbestos. Since the time from asbestos exposure and development of tumors is 20-50 years,
the incidence of malignant mesothelioma is expected to decline [5], after reaching a plateau
around the year 2020. The current incidence rate in Sweden is around 100 new patients
every year since the 1990ties, owing to the rather long latency period and to immigration
from countries where asbestos was banned at a later date or even have yet to be banned.
Even in countries where the use of asbestos has been banned, there may exist communities
that are located in areas contaminated by asbestos, either due to former mining and / or
processing or because of natural presence in the superficial layers of the soil [6].
In addition to MM the serous cavities are frequent locales for metastases. These metastatic
cancers reach the serous cavities by direct invasion, for example from the lungs, ovaries
and gastrointestinal tract. Once in the cavity it may disseminate further along the serosal
surface and enter the lymphatic system via the stomata that normally drain the serous fluid
[7]. Most carcinomas in the pleura are adenocarcinomas, squamous cell carcinomas being
2much less common [8]. Lung cancers and breast cancers are commonly found in the pleura
[8], while ovarian and gastrointestinal cancers are common in the peritoneum. But this
anatomical separation is by no means absolute, and the aforementioned cancers often
appear in both the pleural and peritoneal cavities. Adenocarcinomas present in serosal
cavities are by definition advanced and the prognosis is therefore poor with the mean OS
limited to five months [8-10].
Of all malignancies of the serosal cavities, lung adenocarcinomas (LAC) with pleural
spread are the absolutely most common [11]. Lung cancer is one of the most common
cancer forms worldwide. In Sweden, preventive measures aimed at reducing tobacco
smoking have abated lung cancer to the fifth most common cancer form. Even so, lung
cancer remains the most common cause of cancer related deaths, highlighting the relative
aggressiveness of this cancer form.
1.1.2 Diagnosis
The first symptom of a malignant involvement of the serosal cavities is often the
appearance of a serosal fluid accumulation, also called an effusion. The serosal fluid is
drained by “stomata”, i.e., openings from the cavity directly into the lymphatics. Tumors
growing in the cavity often spread and physically block these stomata, preventing fluid
resorption. 80% of all patients with MM and 15% of all patients with LAC show their
spread to the serosal cavity by an associated effusion [8, 12]. The pleural effusion occupies
space in the thoracic cavity, causing shortness of breath. The effusion is drained to alleviate
the symptoms [13].
This fluid is therefore first biological material available for demonstration of serosal cavity
involvement and microscope diagnosis. Guidelines were recently published showing how
the cytological diagnosis of a MM can be achieved in a majority of cases [14], still
necessitating the more invasive diagnostic techniques with biopsy sampling for the
remaining cases. Once the diagnosis of a malignant condition is established, modern
cytologypathology and histopathology tries to establish the type and origin of the tumor,
using immunocyto- and histochemistry. The diagnostic principles are the same regardless
which cavity is engaged, although the tumor types and their primary locations vary.
As a metastatic manifestation, the spread of a tumor to the serous cavity is often a late event,
and the primary tumor is sometimes already known [15]. Spread of such a tumor to a cavity
can be traced by x-ray related techniques, also before an effusion is built up. The
macroscopical changes in serous membrane morphology must, however, be examined
microscopically by cyto- or histopathology in order to establish the diagnostic basis for
treatment.
1.1.3 Treatment
There are four principal therapy options for fighting cancer: surgery, radiotherapy,
chemotherapy and immunotherapy. Treatments can be given alone, as supplements to each
other or sequential. If a preferred option fails alternative options can be used, or, following
remission, as maintenance therapy to decrease the risk of recurrence. The utility of each
treatment option depends on the diagnosis. One factor influencing the prognosis of a cancer
is the clinical stage. Once a carcinoma reaches a serosal cavity the tumor has reached an
advanced stage where radical resection of the tumor is no longer possible. Similarly, the
primary MM is in most cases non-resectable when detected, i.e., radical surgery seldom
improve OS [16]. The therapeutic option for both primary and metastatic tumors in the
3serosal cavity is therefore in most cases chemotherapy, in some cases after surgical
reduction of the tumor mass.
Thus, for these tumors chemotherapy is the therapeutic option of choice. The standard of
care (SOC) drug regiments used for MM and LAC with pleural spread all have an objective
response rate (ORR) is in the neighborhood of 30-40% [17-21], with an added mean
survival benefit of a mere three months.
1.2 Brief summary of tumor biology
1.2.1 Oncogenes
The cell is the basic building block of all life. Cells ingest and rearrange molecules from the
surrounding environment, to harvest energy from energy rich chemical bonds and then use
this energy for movement and for synthesizing the molecules necessary to sustain itself.
Molecules are step-wise broken down, converted and / or synthesized by macromolecular
machines. Other macromolecules have structural function, signaling function or motor
function, among other functions. The relationships between position, quantity and structure
of macromolecules as well as the flux of metabolites in any given area inside a cell
determine that areas net function. This organization of macromolecules is determined by
feedback processes that up or downregulate genes. Specialized functional centers are called
organelles.
The cells of complex multicellular organisms depend on each other for survival, and each
individual cell must submit to the needs of the organism as a whole. This is achieved
through an additional layer of feedback processes called cellular signaling. Similar to
organelles, the cells in complex multicellular organisms form specialized clusters of cells
called organs. An example feedback process is the release of insulin following increased
blood glucose levels, which in turn signal to muscle cells to increase their glucose uptake,
thus resuming normal blood glucose levels.
A gene is any segment of DNA coding for molecular machines. Genes are transcribed into
either lncRNA, or into mRNA that is subsequently translated into proteins. The sequence of
the gene determines which and in which order nucleotides (for RNA) and thus in turn the
order for amino acids (for proteins) are synthesized, and thereby the structure and function
of the molecular machine. A molecular machine can consist of one or several subunits of
proteins and / or lncRNA.
Non-controlled alterations of DNA are called mutations. A mutation in the coding section
for a protein might alter the function, by changing an amino acid vital for its activity or
structure, or by inserting an improper stop codon. Other than the coding sequence, genes
contain promoter and operator segments, and might have associated enhancer segments.
Mutations in these regions will not alter the molecular machine’s function, but it can alter
the expression levels.
Oncogenes is a collective name for genes that, when acquiring certain mutations, in one
way or another either promotes cell growth [22], such as EGFR (over-activation increase
proliferation) , or promotes or inhibits checks on cell growth, such as MHC class I (pseudo-
functional MCH class I can “hide” a cell from the immune defense[23]) or P53 (altered
function of P53 can prevent or delay apoptosis) [24].
4Fig1: Schematic representation of synthesis and delivery of a molecular machine, in this case a
transmembrane protein. The picture is simplified for visual clarity, for instance, the protein is fully translated
already in the ER, and there is vesicular transport also between the ER and the golgi. 1) A transcription
bubble. The DNA is temporarily unwound, as the frame is transcribed into mRNA by RNA polymerase.
mRNA is then feed into the endoplasmatic reticulum (ER) through pores in the nucleus. 2) The ribosome
translates the mRNA sequence into an amino-acid sequence. The protein is then packaged into a vesicle by
the golgi (3). The final destination of the protein can be much anywhere in the cell, dependent on "adress"
"tags" that the golgi attaches to the vesicle. In this case, the vesicle is carried to its destination by a dynamin
(4), and eventually fuses with the membrane (5). Image printed with permission from Christina Hillerdal ©.
51.2.2 Tumor heterogeneity
A cancer cell, simplified, is a cell inside a multicellular organism that, due to mutations in
oncogenes, becomes insensitive to cellular regulatory mechanisms and adopts the purpose
of a unicellular organism, therefore endlessly multiplying. This will eventually disrupt and
destroy surrounding tissue.
Tumor heterogeneity occurs mainly as a consequence of four factors; 1) the cell type of the
cancer cell origin [25], 2) the mutations developed during carcinogenesis [25, 26], 3)
random mutations in the genetically unstable tumor, creating diversity even within the
tumor cell population [27] and 4) the evolutional pressure, selecting for viable cancer
strains [23, 27].
All tumors start as a single cell mutating into a more rapidly proliferating cell, of which all
daughter cells will carry the same genetic damage. The compact mass of daughter cells
forms a tumor. In this growing mass, eventually further mutations occur, splitting the tumor
lineage into two distinct phenotypes. Later, a cell of either lineage may then pick up a third
(oncogenic) mutation, and so on. In a study investigating colorectal and breast cancers, it
was found that the average tumor have around 80 amino-acid altering mutations, of which
15 seemed to have oncogenic importance [28]. Note however, that the distinction between a
benign tumor cell and a cancerous tumor cell can be fine; premalignant lesions require only
one or a few mutations to turn cancerous. Thus, a tumor burden might develop or might
have developed from the same pre-malignant lesions into cancer on more than one or
occasion [29]. This random creation of a multitude of lineages contributes to tumor
heterogeneity.
Fig2: Schematic presentation of epithelial tissue turning cancerogenous. Each shift towards a more cancerous
phenotype is preceded by oncogenic mutations. Image reprinted under CC license, Learn Oncology ©
(http://learnoncology.ca/wordpress/).
6In complex multicellular organisms, life begins as a single cell that will replicate and
diversify into, for humans, more than 200 different cell types. This is a step-wise process,
where parts of DNA not required for the intended function through various processes
collectively known as epigenetics are made inaccessible. Each further diversification event
closes the door to several “final form” cell types, creating a pyramid of sorts, with stem
cells on top, with decreasing possibility for final forms the further down on the pyramid it
goes, until finally reaching the base of the pyramid, the fully differentiated cells.
Thus, simplified, epigenetics determine which genes are more readily available for
transcription. Consequently, the cell type of origin will determine which macromolecular
machines that are active in the pre-cancerous cell, and thereby which genes that are
“meaningful” to mutate [30]. A mutation in a non-expressed gene is of no relevance, and,
different cancer forms differ in which genes are the most likely to be progress the tumor
cells through the cancerogenesis – by providing a growth advantage, these mutations will
be found in the most aggressive tumor cells, and thereby in the most prominent tumor
lineages [31].
Finally, tumor cells must overcome several “barriers”. One literal barrier is the basement
membrane, a thick matrix of secreted extracellular molecules, which will contain tumors
until they find a way to bypass it. Another example is natural killer cells, cells of the
immune system that will kill any cell that do not meet certain criteria. For instance, if MHC
class I surface protein expression is downregulated it triggers natural killer cell that will kill
the tumor cell. This evolutional pressure therefore selects for cancer strains with MHC
class I mimicry mutations [23].
1.3 Cytostatics
1.3.1 General
While cancers have been treated with herbal remedies since ancient times [32], regular
systemic chemotherapy dates back almost 150 years [33] and the first properly documented
modern clinical trials using chemotherapy was with mustard gas in 1943 [34], Sydney
Farber is still heralded as the father of chemotherapy with his 1947 article that could show
remission for patients with childhood leukemia treated with aminopterin [35]. These
children would later go into recurrence, but the search for other novel drugs able to treat
cancer had started, and in 1964, by the use of combination therapy, a cancer was for the
first time by modern means verifiably cured using chemotherapy [36]. Since then, there has
been an explosion of new cytostatics and combinations there off.
Cytostatic drugs are mostly given systemically and are not per se tumor cell specific, yet
still target tumor cells. This is because the cytostatic drugs targets dividing cells and since
under normal circumstances most cells in the body have relatively few cell divisions, tumor
cells end up being more highly affected [37]. Tumor cell upregulation of metabolism also
helps making tumor cells more susceptible [38]. But it must be noted that rapidly
proliferating benign cells, for instance hair follicle cells and gastro-intestinal cells, are also
more susceptible, giving raise to hair loss and bowel dysfunction, among other common
side effects of chemotherapy [39]. For this reason, all cytotoxic drugs have severe side
effects, and the desire to kill the cancer must be balanced with toxicity for the patient.
7The therapeutic window refers to the concentration range where the drug asserts an effect
on the tumor without causing unacceptable harm to the patient. Depending on the rate of
clearance and inactivation of the drug by the body, primarily by the liver, and the rate of
drug administration, drugs will after each administration remain at an active blood
concentration level for a certain period of time. The tumor is most often not eradicated after
a single administration, which is why the procedure is repeated after allowing the patient
the time needed to recuperate. The number of treatments necessary depends on the drug(s)
and the diagnosis [40, 41].
Fig3: Age-standardized ten-year net survival trends, in adults (aged 15–99) of selected cancers. Patients
from England and Wales were included, spanning from 1971 to 2011. Reprinted from “Repositioning
approved drugs for the treatment of problematic cancers using a screening approach” under PlusOne©
CC.
1.3.2 Classes of cytostatics
Most cytostatic drugs target the replication process. In order to replicate, the cell needs to
synthesize the nucleotides that will be incorporated as complementary strands to both
original DNA strands. Anti-metabolites are a class of drugs that mimic metabolites critical
for dNTP synthesis. The consequence is that enzymes, unable to distinguish between its
natural metabolite and the anti-metabolite, randomly uses or attempts to use the anti-
8metabolite instead of the metabolite. This can lead to inhibition of the enzyme activity, as
the anti-metabolite have a structure that cannot be processed, or, if the metabolite is
properly processed and inserted into DNA, downstreams DNA damaging effects, as the
anti-metabolite will make the DNA unstable or unreadable. Pemetrexed is an example of a
folate acid mimicry. By competing with the intended substrate during TS (thymidylate
synthase), DHFR (DiHydroFolateReductase) and GARFT (glycinamide ribonucleotide
formyltransferase) activity, dNTP synthesis is inhibited, therefore hampering progression
through the S-phase [42].
Fig4: Schematic representation of the cell cycle overlaid with a selection of cytostatics and their respective
targets. Note how most of these drugs directly or indirectly targets the S-phase.
Gemcitabine is an example of an antimetabolite that is inserted into DNA during replication
[43]. Once there, it prevents further elongation of the complementary strand, causing
replication failure and DNA shearing, which will trigger apoptosis. Moreover, gemcitabine
also irreversibly bind the active site of RNR (ribonucleotide reductase) [44], which, like
pemetrexed, inhibits dNTP synthesis.
Carboplatin creates DNA adducts [45], and although not adding alkyl groups to DNA, it
carries out the same function as alkylating agents and is classified as such. In LAC,
carboplatin is combined with gemcitabine (GC) [20] and in MM with pemetrexed (PC) [46,
47]. Failure to exit S-phase triggers DNA repair mechanisms, such as ERCC1 (excision
repair cross-complementation group 1), an enzyme that cuts away the damaged strand,
followed by incorporating dNTPs to the complementary strand [48]. An acute shortage of
dNTPs will lead to this process failing [49] – importantly, the DNA will thus at every
instance where ERCC1 have bound remain single-stranded until more dNTPs are located. It
is well known that platinum drugs cause shearing of DNA, and one could speculate whether
this is the process by which that occurs [50]. In either case, once the DNA repair
9mechanisms are triggered, and no “the DNA is rescued” signal follows, S-phase arrest will
eventually trigger apoptosis [51].
Doxorubicin is an anti-tumor antibiotic, a group of cytostatics so called because they were
first discovered in unicellular organisms, much like penicillin. Common for all anti-tumor
antibiotics is that they target DNA replication. Doxorubicin is a multi-functional drug with
several acutely toxic effects [52], which includes triggering ROS, but the most important
function is DNA intercalation [53] – it inserts itself between the layers of DNA. Once there,
it will interfere with the function of topoisomerase II, a protein that stabilizes double-
stranded DNA, hampering helicase function. This interference leads to replication failure,
and trigger apoptosis. Doxorubicin is therefore also an example of a topoisomerase
inhibitor. The drug combination of cisplatin (a platinum drug, like carboplatin) [54],
doxorubicin and gemcitabine (CDG) have previously been used as a SOC for MM [18].
Once synthesis is completed, the cells enter the mitosis phase. During this phase, DNA is
condensed into chromatin, and pulled apart by microtubules. Microtubules consist of
spiraling loops of tubulins (a dimer of alpha and beta tubulin), 13 for each rotation,
Quickly assembling and disassembling, in a process known as dynamic instability [55].
Mitosis inhibitors either bind tubulins, making assembly difficult, or stabilize the
microtubules, making disassembly difficult. Interfering with this dynamic instability cause
failure to exit M-phase, which triggers apoptosis [56]. Vinorelbine is a mitosis inhibitor used
in LAC and MM [19, 57, 58]. It can be used in combination with cisplatin or gemcitabine,
although their proposed combinatory effect is unclear; cells that due to carboplatin and
gemcitabine cannot exit S-phase also cannot enter M-phase, where vinorelbine exerts its
effect. Thus, this could be a clear-cut example of covering more bases rather than the
combined effect pushing the tumor cell to its limit that we could appreciate for the
combinations GC, PC and CDG.
On top of these drug classes, there are also hormonal agents, and drugs with unknown
mechanism of action. Hormonal agents generally work by restoring function of mutated
proteins or even by inducing differentiation, which puts the cancer cells into G0-phase, thus
not killing them but subverting them [59]. This may inhibit tumor growth, by restoring the
normal levels of proliferate signaling, which, due to the DNA damage tumor cells have
suffered, tips the scale towards apoptosis signaling [60].
1.3.3 Drug sensitivity profile
Drug resistance is a serious concern for treating physicians; solid tumors tend to relapse
following chemotherapy, and when they do, they may have evolved into a more aggressive
phenotype. This can be explained by clonal selection of cancer cells with increased
resistance to given drugs. Each tumor is genetically unstable. Every replication adds a risk
for further mutations, where clones with growth advantage will expand. Thus, in theory, the
larger amount of tumor at the initiation of treatment, the more likely are subpopulations of
resistant cells that will survive and become predominant under the pressure of
chemotherapy [61].
Cytostatics can be classified based on their mechanism of action. Tumor cells, on the other
hand, are not only different depending on the diagnosis, but also inter-individually. These
differences may include variations in the pathways that can be targeted by the cytostatics
used. On top of picking the right drug target for the right tumor, resistances also develop
over time following chemotherapy [62]. For instance, the drug target can be further mutated
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so that the drug can no longer bind or otherwise exert its function, or the tumor cells can
bypass the drug target itself, by instead inhibiting or hyper activating a function
downstream of the target [63]. Even if the vulnerability remain, secondary resistances can
render the drug ineffective, for instance by inactivating the drug, relocating drugs from the
area where they exert their effect or by developing resistance towards the damaging effect
of the drugs. An example of bypassing a function is hyper activation of KRAS following
gefitinib treatment, a drug that targets EGFR, since KRAS is downstream of EGFR [64].
An example of a secondary resistance is upregulation of ERCC1 [65], a molecular machine
which can excise and replace DNA adducts created by platinum drugs. Further, resistances
might have already developed inadvertently in chemotherapy naïve patients, as a
consequence of tumor heterogeneity [66].
Novel mutations causing resistance to cytostatics often do not confer full resistance to the
drugs; as is shown by cell line experiments, increasing the drug concentrations will
eventually overpower the defenses [67] – but you cannot increase concentrations in patients
without unwanted side effects. Most drug regimens are a combination of two or more
cytostatic drugs that oftentimes also includes non-cytostatic drugs that mitigate the side
effects of the cytostatic drugs. Combination therapies are often designed so that the first
drug potentiates the second one, i.e., the combination synergistically turns the tumor cell
non-viable. In other cases drugs in combinations target different functions of the tumor cell,
thereby increasing the likelihood of effect.
1.3.4 Estimation of the tumor cell drug sensitivity profile ex vivo
As the tumor increase its burden on the patient, the total number of replications increase,
thereby increasing the likelihood of acquiring new mutations eventually resulting in a
subpopulation of drug resistant cells. The risk of recurrence decreases with the
effectiveness of the given chemotherapy [61]. The different SOC for MM and LAC used
have an ORR of 30-40% [17-21]. Both patients that are multi-resistant and those multi-
sensitive to chemotherapeutic options would receive only limited benefit from an
individualized choice of drugs. However, it is also likely that many patients are resistant to
one class of drugs but not another. Drug sensitivity profiles have been attempted since long,
using tumor biomarkers, genetic analyze and ex vivo drug exposure of patient own tumor
cells. In theory, perhaps the chaotic reshuffling and mutations of DNA and high
heterogeneity can result in a phenotype or mix of phenotypes perhaps difficult to appreciate
with genetic tests alone. Better then to test the phenotypes directly by ex vivo drug exposure.
Studies of the survival benefit of selecting the most appropriate drugs over the SOC have
shown promising results [68-70]; however, effectiveness varying from one study to another
and with the way drug effects are estimated [71, 72]. Tumor cells from effusions have been
used for this purpose, however, without considering the effects of a varied tumor cell
proportion.
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2 AIMS
The aim of this thesis is to determine the in vitro sensitivity profile of malignant cells
obtained from effusions. The rationale for such an in vitro testing is that the response rate is
currently only 30-40% patients with malignancies in the serosal cavities respond to the
standard of care cytostatic drug regiments. Previous studies attempting drug response
predictions using tumor cells isolated from effusions have had a varying degree of success,
yet none have found their way into regular clinical practice. The overall aim of this thesis is
therefore to further refine the methods used for drug response prediction by increasing the
prediction accuracy.
Specific aims:
Paper I and II To establish drug sensitivity profiles against a battery of 32 drugs, and
compare this data to patient overall survival
Paper III To determine to which degree benign cell presence mask activity of the
tumor cells, and to find ways of performing tumor cell specific assays.
Secondary aims included finding working concentrations, investigating the
combined effect of using two or more drugs compared to drugs as singles
and to investigate the difference between dissociated cells and cells in 3D-
structures.
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3. Methodology and Results
3.1 General methods
The basis for this work was tumor cells isolated from malignant effusions of the pleura,
pericardium or peritoneum. The cells were separated from the effusion liquid using
centrifugation followed by growing them in cell culture medium. In general, there is a mix
of benign and malignant cells in these isolates. The proportion of tumor cells in the samples
was determined by immunocytochemistry (ICC) or flow cytometry (FACS). Both ICC and
FACS used antibodies against the tumor markers mesothelin, EpCAM and / or EMA and
inflammatory cell marker CD45.
Attempts to increase the proportion of tumor cells in the isolates (paper I, II and III) were
made using overnight cell culturing, a technique whose outcome depends on the tumor and
benign cells propensity to adhere or remain in the suspension. Additional methods used for
tumor cell enrichment comprised, filters, manual removal of macroscopic tissue fragments
and magnetic beads labelled with tumor marker EpCAM or with inflammatory cell marker
CD45. Tissue fragments will adhere and spontaneously release dissociated cells. To
decrease dissociation times, the area to volume ratio was increased by shearing larger tissue
fragments into smaller fragments using treatment with trypsin or collagenase under heavy
vortexing.
To determine the sensitivity to different drugs in vitro the isolates were exposed to batteries
of cytostatics for 48 or 72 h, followed by the measuring of their relative survival compared
to an untreated control. The isolates from malignant effusions were also compared to cells
isolated from benign effusions (paper I-III). Finally, the results from the in vitro tests were
compared to outcomes of given treatment as presented in patient journals. Of interest were
overall survival (paper I and II) or RECIST assessment of tumor response (paper III).
RECIST classifies the response as one of four possible outcomes: progressive disease (PD),
when the tumor mass has increased more than 20%, stable disease (SD), when the change
was too small to quantify for PD or PR, partial response (PR), when there was more than
30% decrease in tumor mass and complete response (CR) was there was no evidence of
disease. RECIST is generally evaluated as the change from before initiation of treatment to
the situation 8-12 weeks following initiation of treatment.
3.2 Drug screening using a large battery (Paper I and II)
Cells were isolated in short term cultures from malignant effusions caused by malignant
mesothelioma (Paper I) or from lung adenocarcinoma (Paper II) and from 4 benign
effusions (paper I and II). The cells were seeded in 384-well plates and exposed to a battery
of 32 cytostatics for 72 hours. Each drug was tested at 4 different concentrations, followed
by a colorimetric live-dead assay. The results were recorded using an automated laser
confocal microscope that measured the color of each cell individually. Images were
analyzed through automated software that calculated the number of live and dead cells.
While some mesothelioma cell isolates were sensitive to a broad spectrum of drugs, other
appeared resistant to all tested cytostatics. The sensitivity profile differed, i.e., some isolates
were sensitive to one set of drugs while being killed by other drugs. We were able to find a
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correlation of in vitro drug susceptibility and patient overall survival, as well as the relative
expression of two proteins involved in general drug resistance (ERCC1 and RRM1) for
malignant mesotheliomas (Paper I) but not for lung adenocarcinomas (Paper II).
Mathematical compensation for the benign admixture, by assuming benign cells from
effusions of benign origin would behave similarly to benign cells from effusions of
malignant origin, showed an increased correlation of our in vitro determined general drug
susceptibility to patient overall survival.
3.3 Tumor specific drug screening (Paper III)
Based on experiences from paper I and II, we identified two limitations with the employed
sensitivity testings:
1. The admixture of benign cells may have a significant impact on survival data from tumor
isolates as a whole. More precisely, the mathematical compensation suggested that tumor
cells and benign cells have different response to cytostatics, possibly resulting in an error
related to the relative ratio between the different cell types.
2. Many of the drugs were at given concentrations ineffective in more cases than described
response rates in vivo.
At the Karolinska University Hospital, Sweden, drugs are given as combination therapies
for lung adenocarcinomas involving the pleural, pericardial or peritoneal cavities
(carboplatin plus gemcitabine) and for malignant mesotheliomas (pemetrexed plus
carboplatin). To clarify if both used drugs were effective and to reveal possible synergistic
effects, we found it relevant also to test the effect of administrating the drugs in
combination.
This approach, however, necessitated a downscaling from 32 to 6 tested drugs in order to
allow optimization of the methodology. We included the drugs that are relevant in the
Swedish clinical setting (carboplatin, gemcitabine and pemetrexed). For comparison, we
also included drugs from common alternative first line chemotherapy (vinorelbine, as a
single, or in combination with carboplatin or gemcitabine) as well as an alternative regimen
(doxorubicin, in combination with carboplatin and gemcitabine). Finally, even though
carboplatin today is more commonly used, carboplatin can be exchanged with cisplatin in
all combinations described above, and this drug was therefore also included.
The issue of insensitivity to clinical drug concentrations was solved by using stepwise
alterations of the concentrations until we could identify “working” concentrations; levels at
which the inter-isolate variation would distinguish sensitive from insensitive ones.
Pemetrexed only rarely showed effect at 48 hours, even at high concentrations. Therefore,
pemetrexed was measured using cell cycle histograms, comparing the cells in early S-phase
of sample and control, instead of comparing survival.
The interfering effects of benign cells present in the effusion could be demonstrated by
comparing survival of MACS-beads enriched and depleted fractions of the same isolate and
by comparing the benign and tumor specific apoptosis in unaltered isolates using FACS
annexin-V / PI apoptosis assays. Tumor specific measures were ensured by using
fluorescence-labeled antibodies against tumor markers. This disturbing effect of benign
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cells was substantial when the tumor cells amounted to less than 75% of cells present,
which was the case for most isolates. The FACS viability assays were found superior,
because the MACS-beads often failed to increase the tumor proportion to 75% or above.
With this study design it was also possible to show that drugs, even when they as singles
did not elicit any response, could have a profound effect when combined. The in vitro
results of pemetrexed and carboplatin of nine isolates were compared to patient outcome,
estimated as RECIST scores at 8-12 weeks after initiation of treatment and described in the
patients’ journals. There are four possible such scores: progressive disease (PD) when the
tumor mass has increased  20% on evaluation, stable disease (SD) when the change was
too small to qualify for PD or PR, partial response (PR) when there was 30% decrease in
tumor mass and complete response (CR) where there was no evidence of disease when
evaluating effect of treatment. Out of the nine isolates, seven could correctly predict the
scores. However, no conclusions can be drawn regarding sensitivity and specificity of the
prediction based on this limited number of patients.
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4. SUMMARY
4. 1 Discussion
The mean overall survival for malignant mesothelioma is around a year, and around five
months for metastatic lung adenocarcinoma with pleural involvement. For both situations
chemotherapy is in most cases the only available treatment. The standard of care first line
of chemotherapy has varied historically, and from hospital to hospital. Common for all
these treatments is a roughly 30-40% objective response rate, resulting in similar overall
survival.
Cytostatics can be classified based on their general mechanism of action. Still, drugs within
the same class may differ in their specific mechanism of action, including their specific
target(s). The biologic differences in tumors from different patients influence the
susceptibility to cytostatics, depending on the drug specific mechanisms of action.
Therefore, a guided choice of cytotoxic drugs based on the analysis of drug sensitivity
would increase OS by virtue of increasing the response rate. This working hypothesis is
supported by the results from in vitro testing, with highly variable patterns for the different
isolates (paper I-III).
There was no single patient isolate that was sensitive to only a single microtubule agent
(paper I). All patient isolates but one with sensitivity to docetaxel also reacted to paclitaxel,
while more than half of the isolates sensitive to at least one taxane were sensitive to at least
one vinca alkaloid too. Likewise, sensitivity to actinomycin D is often telling of sensitivity
to daunorubicin. Some isolates were multiresistant and some were multisensitive, while
other isolates were clearly sensitive to one class of cytostatics and as clearly resistant to
another (cf paper II, Figure 2). Thus, resistance to one class of cytostatics does not
necessarily mean resistance to another class.
There are many specific mutations, that alters expression or function in a way causing
resistance or sensitivity towards certain cytostatic drugs. One example is gain of function
mutation in some lung adenocarcinomas is the epidermal growth factor receptor deficiency
(EGFR), an oncodriver gene. The mutation is an event early during carcinogensis, and all
tumor cells will therefore carry this same genetic deficiency. Specific EGFR inhibitors will
then have a good effect on these tumors, although a later second mutation in the same gene
will block the effect of the EGFR inhibitor, thereby causing relaps of the disease. Other
lung cancers show mutated KRAS, which is another protein in this replication activating
pathway, downstreams of EGFR. Such a gain of function mutations in KRAS will then not
be influenced by targeting the upstream EGFR inhibitor.
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An alternate way of predicting sensitivity or resistance to certain drugs is to demonstrate
the expression of factors related to gene expression or DNA repair. These compounds can
be shown on either as RNA expression or as proteins by immunocytochemistry. Two
substances that have been suggested as such prediction markers for chemoresistance are
ERCC1 and RRM1. ERCC1 is involved in DNA repair mechanisms and RRM1 in RNA
synthesis. When analysed on the mesothelioma samples there seemed to be a correlation
between general drug resistance and high RRM1 expression, while no such tendency could
be seen in lung cancers. The simultaneous analyses of ERCC1 showed no correlation to the
drug sensitivity pattern. It may well be that the synthesis and repair of nucleic acids,
counteracting a drug’s mode of action, can be rescued also by other factors and alternate
pathways, which makes this way of predicting response to therapy uncertain.
These studies are based on primary tumor cell isolates obtained from effusions, most of
them from the pleura, but also some from the peritoneum and the pericardium. These cells
can be assumed to reflect the “current” situation of the cancer, representing a part of the
tumor with metastatic capacity and perhaps also representing more aggressive clones of the
tumor mass. Malignant effusions also contain a mixture of benign immune cells and
macrophages together with benign mesothelial cells. The mathematical compensation for
the benign contribution (paper I and II) was based on the drug sensitivity profile of benign
cells in four effusions from patients without malignant diagnoses.
The influence of such benign cells could better be shown when their proportion was altered
experimentally (Paper III). Surprisingly the effect was unpredictable. While in some cases
tumor enrichment increased drug sensitivity, in other isolates the effect was reversed. This
effect of the benign “noise” can thus not be accurately determined by comparing with cells
from benign effusions, but should be considered in each single case. The use of FACS
circumvents this problem, since this allows the specific analysis of tumor cells. This
“noise”-effect became minute, when the tumor cells represented >75% of the cellular yield.
Effusions with such richness in tumor cells often, however, represent a more advanced
stage of the cancer, with less effects of cytostatics. Effusions with less tumor cells are
therefore more interesting in this context, and in these cases FACS is a clearly
advantageous alternative.
It is well known that the biology and function of cancer cells not only depend on intrinsic
factors but also on their microenvironment. Thus when growing them on a hydrophobic
support, they attach less and spread less on the plastic surface compared to growing them in
hydrophilic flasks. Instead they tend to form spheroids, with numerous desmosomes with
some similarities to the situation in dense cultures. Such confluent cultures as well as
spheroids decrease their sensitivity to cytostatics. As expected, growing the cells on the
hydrophobic support increased the drug resistance in an unpredictable way. However, it
was difficult to create uniform spheroids, therefore, better protocols or some manner of
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mathematical compensation would have been necessary for inter-isolate comparisons.
The drug concentrations used for the broad screening (paper I and II) were calculated based
on area of curve calculations of patient drug blood levels; corresponding concentrations in
the extracellular microenvironmet around the tumor cells is not known. While clinical
responses in the 30-40% range is seen with drugs, such as cisplatin, carboplatin,
gemcitabine and pemetrexed, there was complete or almost complete resistance to these
drugs in the experimental setting (Paper I and II). In order to find a concentration where the
test discriminated between more and less sensitive isolates during the 48 hours exposure,
the drug concentration levels were elevated to beyond that of the previously used
concentrations (paper III). The risk with this approach is that supraclinical concentrations
might activate other apoptosis pathways than what occurs in the patient.
The short time for culturing the cell isolates (48 hours) was selected for several reasons.
First, with longer times it may become necessary to change medium during exposure. The
mechanical handling of the culture when changing medium may influence the cells in an
unpredictable manner and there will be a random factor depending on how many
supernatant and attached cells are lost. Then, a clinically useful predictive test preferably
provides the results within a reasonable time. For this test, isolation, two days culturing and
analyzing the results, can be performed within a week. It should also be considered that
longer culturing may result in expansion of certain tumor clones that may give misleading
result.
We managed to find “working concentrations”, concentrations that at 48 hours gives rise to
differences in response (paper III). Pemetrexed is a drug that in general will not elicit
apoptosis during the short exposure, even at high concentrations. Effects of the drug could
instead be shown by analyzing the content of DNA by FACS, estimating the proportion of
cells in S-phase arrest using a cell cycle distribution histogram. Variations thereof were
able of distinguishing sensitive and non-sensitive isolates.
Attempts to predict drug effect often correlated with the clinical outcome (paper III),
although the number of patients should be expanded for a final evaluation of the predictive
possibilities. Therefore, before personalized medicine based on drug sensitivity assays can
become a reality, these assays must prove their reliability in predicting the patient response
to standardized regimens.
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4.2 Conclusions
* There is a great diversity in in vitro drug sensitivity profiles.
* As with cell lines, pemetrexed is best measured as S-phase
arrest at short exposure assays
* Interference of benign cells is substantial in isolates with < 75%
tumor cells
* Cell sorting techniques employing filters and MACS-beads can
be used to increase the tumor proportion at least 2-fold (for
isolates with <45% tumor cells) for at least 70% of all isolates.
* FACS can measure the tumor specific apoptosis using
fluorescence labeled annexin-V, PI and antibodies against tumor
markers
* FACS seem to outperform MACS-beads and filters when tumor
proportions are low
* Growing tumor cells into artificial spheroids increase their
resistance to drugs
4.3 Future perspectives
This thesis describes a work aimed at optimization of experiment conditions for patient-own
tumor cells derived from malignant effusions in short term cultures. The purpose is to
establish a drug sensitivity profile for said tumor, with an ultimate purpose of predicting
patient drug response. When these predictions become sufficiently accurate, they can be used
to guide a personalized choice of drugs, instead of the statisticially most likely effective drug
according to standardized programs. Established regimens have objective response rates in
the ranges of 30-40%, and it has been shown that drug responders have an improved overall
survival over drug non-responders [73]. It was also found (papers I, II and III) from
experiments with ex vivo cultures that resistance to one drug regiment does not necessitate
resistance to another, there is reason to believe that guided choice of therapy could have a
survival advantage over conventional regimens.
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Survival index (SI), comparing the proportion of live and dead cells of a treated sample with
an untreated control is the most commonly used measure to evaluate the cytostatic effect on
tumor cells in vitro. However, different studies using SI as outcome are difficult to compare if
different drug concentrations are used. Paper III showed that short term (48 h) primary tumor
cell isolates should (a) be tumor specific and (b) use an extended range of concentrations. All
cytostatic drugs tested in paper III, with the possible exception of pemetrexed, functions as
standard inhibitors, where the maximal efficiency is complete death of the entire cell
population. Therefore, for these drugs and at 48 h incubation, the concentration which yields
an SI of 0.5 is always equal to the half maximum effective concentration (EC50), and further,
the drugs have near linear dose-response relationship shortly following minimal inhibition
and shortly before maximal inhibition (see figure 5, below).
Figure 5: Celline M-14-K tested at 24 different
concentrations of gemcitabine and analyzed as a
standard inhibtor curve in prism v6.0. Note the blue
arrows indicating minimal and maximun efficiency,
and the near linear relation of survival index and
concentration between the red lines.
Thus, EC50 values are readily calculated using a straight-line equation, as long as there are at
least two concentrations with sufficient distance from each other in the linear range. Using
cell line data, we could determine that the accuracy of that calculation is within 0.85 to 1.15
fold compared to the 24 data point standard inhibitor curve for gemcitabine, and within 0.95
to 1.05 fold for carboplatin.
Thus, assuming sufficiently high concentrations are used to land within the effective range
and assuming appropriate distance between the tested concentrations, SI can instead be
reported as EC50 with minimal effort. This simple adaption would produce higher quality
meta-studies in the field of cancer research this thesis concerns.
Of course, the relevance of EC50, i.e., the predictive value, still need confirmation through
correlation with the clinical routine, by comparing obtained ex vivo drug sensitivity profiles
with patient outcome. The obvious continuation of the optimization work herein would be a
large cohort study using the methods and strategies just presented. Assuming a positive
outcome, that future study could then be presented before an ethics committee, hopefully
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resulting in a follow up clinical trial of guided choice of therapy as one arm and the
conventional regimens as the other arm.
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